URAC Rare Disease Pharmacy Center of Excellence — Frequently Asked Questions
Last updated: April 2026
URAC Rare Disease Pharmacy Center of Excellence Certification is the quality designation that distinguishes specialty pharmacies operating at an elite standard of rare and orphan disease care. Fewer than 25 pharmacies in the United States hold it. These are the questions IHS hears most often from pharmacies evaluating whether and how to pursue it.
About the Certification
What is URAC Rare Disease Pharmacy Center of Excellence Certification?
URAC Rare Disease Pharmacy Center of Excellence Certification is a specialized quality designation for specialty pharmacies that demonstrate advanced capabilities in serving patients with rare and orphan diseases. It adds five standards to URAC Specialty Pharmacy Accreditation — covering rare disease-specific patient assessment, disease-specific education programs, multidisciplinary care collaboration, population-level analytics, and a continuous quality improvement program evaluated against rare disease outcomes. Only approximately 23 specialty pharmacies in the United States currently hold this designation.
Is this a separate accreditation from Specialty Pharmacy Accreditation?
No. URAC Rare Disease Pharmacy Center of Excellence Certification is not a standalone program. It is an additional certification layer that builds on URAC Specialty Pharmacy Accreditation. An organization must hold or be actively seeking URAC Specialty Pharmacy Accreditation (or another URAC program with a specialty patient management requirement) before it can pursue Rare Disease Certification. The five additional standards are evaluated on top of the full baseline accreditation — not instead of it.
What qualifies as a rare or orphan disease for URAC eligibility?
URAC's eligibility requirement references rare and orphan medications — drugs designated under the Orphan Drug Act for conditions affecting fewer than 200,000 people in the United States. Common rare disease categories served by certified pharmacies include hemophilia and bleeding disorders, lysosomal storage disorders, neuromuscular diseases (including spinal muscular atrophy and Duchenne muscular dystrophy), hereditary angioedema, enzyme replacement therapies, and other ultra-rare conditions. Your pharmacy must be actively dispensing at least one such medication to qualify.
How many specialty pharmacies hold this certification?
Approximately 23 specialty pharmacies in the United States currently hold URAC Rare Disease Pharmacy Center of Excellence Certification. This is an intentionally small and selective group. The certification is designed to distinguish pharmacies that genuinely operate at an elite standard of rare disease care — not to serve as a widely distributed credential.
What role did NORD play in developing this certification?
URAC developed the Rare Disease Pharmacy Center of Excellence Certification with input from NORD — the National Organization for Rare Disorders — to ensure the standards reflect genuine best practices in rare disease patient care. NORD's involvement means the certification addresses the care dimensions that matter to the rare disease patient community, not only the operational dimensions that matter to payers and manufacturers.
Eligibility and Who Needs It
Who needs URAC Rare Disease Pharmacy Center of Excellence Certification?
Any specialty pharmacy that dispenses rare or orphan medications and wants access to limited-distribution drug networks, manufacturer preferred distribution agreements, or competitive differentiation in rare disease therapeutic categories. The commercial pressure is real: manufacturers of rare and orphan drugs frequently restrict distribution to pharmacies that can demonstrate the specialized patient management capabilities that Rare Disease Certification documents. Pharmacies without it face significant barriers to rare disease drug access.
Can a pharmacy pursue Rare Disease Certification before completing Specialty Pharmacy Accreditation?
Yes, with conditions. A pharmacy can be actively seeking Specialty Pharmacy Accreditation while simultaneously pursuing Rare Disease Certification. However, the Rare Disease application will not receive a final decision until the underlying accreditation is in place. IHS typically structures these as a coordinated dual engagement to align timelines and eliminate redundant documentation effort — your team should not be building two separate documentation packages when substantial overlap exists.
Does Rare Disease Certification guarantee manufacturer limited-distribution network access?
No. Certification is a necessary condition for many conversations, not a guarantee of any specific network access. Manufacturers of rare and orphan drugs evaluate pharmacy partners on multiple criteria — geographic coverage, patient population, clinical capabilities, operational capacity, and demonstrated quality. URAC Rare Disease Pharmacy Center of Excellence Certification is the recognized independent quality signal that opens the manufacturer conversation. What happens in that conversation depends on your organization's full profile.
The Standards and Survey
What are the five additional standards?
The Rare Disease certification adds five standards to the baseline specialty pharmacy accreditation:
- Rare disease-specific clinical assessment — individualized assessments integrated into patient management for each rare or orphan condition dispensed, not generic specialty pharmacy protocols
- Disease-specific education and support — structured education programs for patients, caregivers, providers, and payers tailored to each specific rare disease in your portfolio
- Multidisciplinary team collaboration — documented coordination among pharmacists, care coordinators, clinical specialists, and treating providers with evidence of actual collaboration events
- Data collection and analytics — population-level tracking of clinical outcomes, adherence, and quality indicators for the rare disease patient population
- Continuous quality improvement — a CQI program specifically evaluated against rare disease performance measures with evidence of improvement activity
What does URAC evaluate in the Rare Disease survey?
URAC evaluates the five Rare Disease standards through document review, patient file audit, and policy assessment. Surveyors look for disease-specific clinical assessments in patient records (not generic templates applied across all conditions), education content tailored to the specific rare disease (not general specialty pharmacy patient education), documented evidence of multidisciplinary team collaboration (meeting records, care plan notes, provider communications), analytics demonstrating rare disease patient population tracking, and CQI reports with rare disease-specific performance measures and improvement activity.
What is the most common reason pharmacies fail Rare Disease Certification?
The most common failure is applying generic specialty pharmacy processes to rare disease patients without disease-specific modification. Pharmacies with strong general specialty pharmacy operations frequently assume their existing patient management and education programs will satisfy the Rare Disease standards — they do not. URAC requires specificity. A hemophilia patient management protocol that is structurally identical to a rheumatoid arthritis protocol fails the specificity requirement regardless of how well-documented the general protocol is. IHS addresses this directly in the gap analysis phase before any documentation effort is invested.
What is a multidisciplinary team for URAC Rare Disease purposes?
A multidisciplinary team means documented collaboration among multiple care disciplines involved in the rare disease patient's care — specialty pharmacists, care coordinators, clinical pharmacists or nurses with rare disease expertise, and external treating providers including specialists and primary care physicians. URAC requires documentation of actual collaboration events, not just an organizational chart. Meeting records, case review notes, and provider communication logs are the evidence types URAC evaluates. Organizations that have functioning multidisciplinary teams but lack documentation of collaboration events will not satisfy this standard.
Timeline and Process
How long does certification take?
Timeline depends on your existing accreditation posture. If pursuing Rare Disease Certification concurrently with Specialty Pharmacy Accreditation, the standards are integrated into the full accreditation timeline — typically 12-18 months. If your organization already holds Specialty Pharmacy Accreditation, Rare Disease Certification preparation can proceed on a compressed timeline — typically 6-12 months — depending on how much rare disease patient management infrastructure is already documented and generating audit-ready evidence.
How does IHS structure the engagement?
IHS structures Rare Disease engagements in four phases: eligibility confirmation and gap analysis against the five additional standards; policy and program development including disease-specific assessment protocols, education program frameworks, multidisciplinary documentation structures, analytics frameworks, and CQI program design; mock review auditing patient files and program documentation against the five standards before URAC sees them; and application support and RFI response through the final decision. See the full service page for detail on each phase.
How does URAC Rare Disease Certification compare to ACHC specialty pharmacy programs?
URAC and ACHC each offer specialty pharmacy accreditation programs, but only URAC offers a Rare Disease Pharmacy Center of Excellence designation. ACHC does not have an equivalent rare disease-specific overlay certification. For pharmacies focused specifically on rare and orphan disease therapeutic categories and manufacturer network access, URAC's program is the relevant credential. See our specialty pharmacy accreditation comparison for a full side-by-side analysis.
Working with IHS
Why work with IHS on URAC Rare Disease Certification?
Thomas G. Goddard, JD, PhD, served as the Chief Operating Officer and General Counsel of URAC — the organization that wrote and administers these standards. That experience is not a marketing credential. It means IHS understands how URAC evaluates these standards from the inside: what surveyors look for, where organizations consistently fall short, and what documentation actually satisfies each requirement versus what merely addresses it on paper. IHS also coordinates Rare Disease Certification with Specialty Pharmacy Accreditation as a single integrated engagement when applicable — one team, one documentation effort, aligned timelines.
Does IHS consult on both Specialty Pharmacy Accreditation and Rare Disease Certification?
Yes. IHS provides consulting across both programs and typically structures them as a coordinated engagement for pharmacies pursuing both simultaneously. For pharmacies that already hold Specialty Pharmacy Accreditation, IHS structures the engagement around the five Rare Disease standards exclusively, building on your existing accreditation posture rather than duplicating preparation already completed.
Schedule a Free Discovery Session
If your pharmacy dispenses rare or orphan medications and you have questions about URAC Rare Disease Pharmacy Center of Excellence Certification — eligibility, timeline, what your current accreditation posture means for the path forward — IHS offers a complimentary discovery session. Bring your drug portfolio and your accreditation history.